#ASYS

StockTitan

@stocktitan.net

3 months ago

Amtech Reports Fourth Quarter Fiscal 2025 Results Amtech Systems, Inc., a manufacturer of equipment and consumables enabling AI semiconductor device packaging and advanced substrate fabrication, today reported results for its fourth quarter ended September 30, 2025.. Net revenue of $19.8 million Cash of $17.9 million Cash provided by operations of $2.3 million GAAP net income of $1.1 million Non-GAAP...

#ASYS Amtech Reports Fourth Quarter Fiscal 2025 Results

www.stocktitan.net/news/ASYS/amtech-reports...

StockTitan

@stocktitan.net

3 months ago

Amtech Reports Preliminary Fiscal 2025 Fourth Quarter and Full Year Results Amtech (NASDAQ: ASYS) reported preliminary, unaudited fiscal 2025 results for the quarter and full year ended September 30, 2025. Key metrics: Q4 net revenue $19.8M (above guidance high end of $19M), Q4 adjusted EBITDA $2.6M (13% of revenue), and cash $17.9M (up $2.3M QoQ). For the full year, net revenue $79.4M, adjusted EBITDA $5.4M, and cash increased $6.8M YoY. The company previously guided Q4 revenue $17–$19M and mid-single-digit adjusted EBITDA margins. Final audited results and GAAP-to-non-GAAP reconciliation will be released on December 10, 2025 after market close, followed by a conference call at 5:00 PM ET.

#ASYS Amtech Reports Preliminary Fiscal 2025 Fourth Quarter and Full Year Results

www.stocktitan.net/news/ASYS/amtech-reports...

Shinji Izuka

@shinjiizuka.bsky.social

5 months ago

Honored to be invited to the 15th Congress of the Egyptian Society of Rheumatology & Clinical Immunology (EGYSIR 2025) Online Review Course!

I’ll present “Anti-synthetase syndrome—an update: from phenotype recognition to precision therapy.”

#Myositis #ASyS

Shinji Izuka

@shinjiizuka.bsky.social

6 months ago

Beyond simple positivity: dissecting anti-PL-12 antibodies as a blueprint for future therapeutics in anti-synthetase syndrome Shinji Izuka; Beyond simple positivity: dissecting anti-PL-12 antibodies as a blueprint for future therapeutics in anti-synthetase syndrome, Rheumatology,

B cell-targeted therapies (CAR-T, T cell engagers) are reshaping autoimmune disease treatment.

In my editorial, I discuss how mass spectrometry dissection of anti-PL12 antibodies in #ASyS (Ali & Troelnikov et al.) may pave the way for precision B cell therapies.

doi.org/10.1093/rheu...

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Small-cap stocks with improving money flow, Mon Aug 18th - #UFCS #STOK #PASG #MLAB #LIND #KALA #IPA #HITI $GDRX #EWCZ #XNET #TBCH #RCMT #COLL #BGFV #ASYS #VTAK #QD #NPKI #MOV #GNTY #WINA - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

7 months ago

Amtech Reports Third Quarter Fiscal 2025 Results Amtech Systems (NASDAQ: ASYS) reported its Q3 fiscal 2025 results, with net revenue of $19.6 million, representing a 26% increase from the previous quarter but a 27% decrease year-over-year. The company achieved GAAP net income of $0.1 million ($0.01 per share) and non-GAAP net income of $0.9 million ($0.06 per share).Key financial metrics include cash position of $15.6 million, customer orders of $21.7 million, and a backlog of $21.2 million. The company's gross margin improved to 46.7%, benefiting from a $1.0 million Employee Retention Credit refund. Normalized gross margin excluding the ERC was 41.5%.Looking ahead, Amtech expects Q4 fiscal 2025 revenues between $17-19 million, with growth in AI-related equipment sales partially offsetting continued softness in mature node semiconductor products. The company projects adjusted EBITDA margins in the mid-single digits.

#ASYS Amtech Reports Third Quarter Fiscal 2025 Results

www.stocktitan.net/news/ASYS/amtech-reports...

StockTitan

@stocktitan.net

10 months ago

Amtech Reports Second Quarter Fiscal 2025 Results Amtech Systems (NASDAQ: ASYS) reported disappointing Q2 FY2025 results with net revenue of $15.6 million, down 36% from Q1 and 39% YoY. The company posted a GAAP net loss of $31.8 million ($2.23 per share) and a non-GAAP net loss of $2.3 million. The poor performance was attributed to a delayed $4.9 million shipment and weakness in the mature node semiconductor market. The quarter saw significant non-cash charges including $22.9 million in impairment charges and $6.0 million in inventory write-downs. Despite challenges, cash position improved to $13.4 million. For Q3 FY2025, Amtech expects revenues of $16-19 million, with growth in advanced packaging equipment offsetting lower mature node semiconductor sales. Management remains optimistic about long-term prospects in advanced packaging equipment and AI infrastructure investments.

#ASYS Amtech Reports Second Quarter Fiscal 2025 Results

www.stocktitan.net/news/ASYS/amtech-reports...

StockTitan

@stocktitan.net

10 months ago

Amtech Systems to Announce Fiscal Second Quarter 2025 Financial Results on Monday, May 12, 2025 Amtech Systems (NASDAQ: ASYS), a manufacturer of equipment and consumables for semiconductor fabrication and packaging, has scheduled its fiscal second quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call at 5:00 pm ET on the same day.CEO Robert Daigle and CFO Wade Jenke will lead the call, providing a quarterly overview and discussing current business conditions, followed by a Q&A session. Investors can join via phone (+1-800-717-1738 for domestic, +1-646-307-1865 for international) or through a live webcast available on the company's investor relations website.

#ASYS Amtech Systems to Announce Fiscal Second Quarter 2025 Financial Results on Monday, May 12, 2025

www.stocktitan.net/news/ASYS/amtech-systems...

StockTitan

@stocktitan.net

11 months ago

Amtech Q2 Revenue Warning: Customer Dispute and Chip Slowdown Impact Outlook, but AI Demand Surges Semiconductor equipment maker cuts Q2 revenue forecast to $15-16M, faces customer dispute and industry headwinds. Strong AI-related orders offer bright spot.

#ASYS Amtech Provides Second Quarter Fiscal 2025 Financial Guidance Update

www.stocktitan.net/news/ASYS/amtech-provide...

StockTitan

@stocktitan.net

1 year ago

Q1 Earnings: Amtech Systems Delivers Surprise Profit as Margins Surge 540 Basis Points Amtech Systems exceeds Q1 expectations with $24.4M revenue and $0.3M net income. Strong cash flow generation and improved margins signal operational momentum despite market challenges.

#ASYS Amtech Reports First Quarter Fiscal 2025 Results

www.stocktitan.net/news/ASYS/amtech-reports...

StockTitan

@stocktitan.net

1 year ago

Amtech Systems Posts $101.2M Revenue, Achieves 4 Straight Quarters of Positive EBITDA Despite Challenges Amtech Systems reports mixed FY2024 results with $101.2M revenue, achieves debt-free status and $7M in cost savings while maintaining positive adjusted EBITDA streak.

#ASYS Amtech Reports Fourth Quarter and Year End Fiscal 2024 Results

#news #StockMarket #investing

www.stocktitan.net/news/ASYS/amtech-reports...

StockTitan

@stocktitan.net

1 year ago

Amtech Systems Sets Q4 & FY2024 Earnings Call for December 9 | ASYS Stock News Amtech Systems announces Q4 and fiscal 2024 earnings release, followed by conference call with CEO Robert Daigle and CFO Wade Jenke to discuss results and business outlook.

#ASYS Amtech Systems to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on Monday, December 9, 2024

#investing #StockMarket #stocks

www.stocktitan.net/news/ASYS/amtech-systems...

Treavor Alvarado

@djtrevi.bsky.social

1 year ago

Unveiling the Unmatched Mastery of A*S*Y*S & Marie Vaunt in 'Give Me Acid': The King and Queen of Acid Reign Supreme In the vibrant world of electronic music, the names A*S*Y*S and Marie Vaunt shine brightly. Their latest collaboration, "Give Me Acid," is stirring excitement among fans and industry insiders. With a ...

Unveiling the Unmatched Mastery of A*S*Y*S & Marie Vaunt in 'Give Me Acid': The King and Queen of Acid Reign Supreme

#Techno #MarieVaunt #ASYS

www.ilovetoraveepic.com/post/unveili...